Difference between revisions of "Part:BBa K613013"
(→In vitro characterization) |
(→=In vitro characterization) |
||
| Line 5: | Line 5: | ||
| − | + | ==In vitro characterization== | |
| − | [[Image:EPFL2011_MITOMI_WebLogo_V36F.png| | + | [[Image:EPFL2011_MITOMI_WebLogo_V36F.png|700px]] |
===In vivo characterization=== | ===In vivo characterization=== | ||
Revision as of 18:43, 21 September 2011
TetR V36F mutant
TetR with a point mutation V36F.
In vitro characterization
In vivo characterization
This TetR mutant was characterized in vivo by putting it into pSB3K1 under a constitutive promoter (J23116). This plasmid was cotransformed with J61002 harbouring RFP under pTet promoter (B0040) in DH5alpha cells. Cells were grown in a medium containing Kanamycin & Amplicillin plus different concentrations of ATC, ranging from 0 to 2000 ng/mL. OD600 absorbence and RFP fluorescence were measured every 10 minutes during 12 hours on a platereader machine.
Induction curves
Fluorescence measurements (RFUs) were normalized by OD600 values.
Dose-response curve
Fluorescence measurements (RFUs) were normalized by OD600 values. For each ATC concentration, we estimated the steady-state fluorescence expression by averaging the measurements over the last hour.
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]